After finishing at $0.82 in the prior trading day, Kezar Life Sciences Inc (NASDAQ: KZR) closed at $0.80, down -2.89%. In other words, the price has decreased by -$0.0237 from its previous closing price. On the day, 977527 shares were traded.
Ratios:
Our goal is to gain a better understanding of KZR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.66 and its Current Ratio is at 11.66. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
On December 08, 2021, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $19.Wells Fargo initiated its Overweight rating on December 08, 2021, with a $19 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KZR now has a Market Capitalization of 58.06M and an Enterprise Value of -124.38M. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.08 while its Price-to-Book (P/B) ratio in mrq is 0.31. Its current Enterprise Value per Revenue stands at -17.77 whereas that against EBITDA is 1.25.
Stock Price History:
Over the past 52 weeks, KZR has reached a high of $3.13, while it has fallen to a 52-week low of $0.67. The 50-Day Moving Average of the stock is 0.9144, while the 200-Day Moving Average is calculated to be 1.2298.
Shares Statistics:
The stock has traded on average 717.54K shares per day over the past 3-months and 1.05M shares per day over the last 10 days, according to various share statistics. A total of 72.78M shares are outstanding, with a floating share count of 60.30M. Insiders hold about 15.01% of the company’s shares, while institutions hold 66.81% stake in the company. Shares short for KZR as of Mar 15, 2024 were 3.38M with a Short Ratio of 4.71, compared to 3M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.64% and a Short% of Float of 4.80%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.25 and a low estimate of -$0.41, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.26 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.02 and -$1.83 for the fiscal current year, implying an average EPS of -$1.35. EPS for the following year is -$1.25, with 6 analysts recommending between -$0.85 and -$1.55.
